Toral Surti, MD/PhD
DownloadHi-Res Photo
Cards
Appointments
Psychiatry
Primary
Contact Info
About
Titles
Associate Professor of Psychiatry
Appointments
Psychiatry
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Research Fellowship
- Yale University School of Medicine and VA Connecticut Healthcare System (2014)
- Research Fellowship
- Yale University School of Medicine (2012)
- Residency
- Yale University School of Medicine (2011)
- MD/PhD
- University of California at San Francisco (2007)
- BS
- Yale College, Molecular Biophysics and Biochemistry (1998)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Toral Surti's published research.
Publications Timeline
A big-picture view of Toral Surti's research output by year.
Deepak Cyril Dsouza, MBBS, MD
John Krystal, MD
Daniel DiMaio, MD, PhD
Geena Fram
Vinod Srihari, MD
Anahita Bassir Nia, MD
11Publications
188Citations
Publications
2024
Psychotic Disorders and Schizophrenia
Surti T. Psychotic Disorders and Schizophrenia. 2024 DOI: 10.1016/b978-0-323-95702-1.00074-9.Peer-Reviewed Original ResearchConceptsPsychotic disordersSymptoms of schizophrenia-spectrum disordersDifferential diagnosis of schizophreniaSchizophrenia spectrum disordersDiagnosis of schizophreniaDecreased emotional expressionNon-psychiatric conditionsAssociated with increased disabilityPsychotic symptomsDisorganized speechDisorganized behaviorCognitive symptomsPsychotic diseasesEmotional expressionSchizophreniaLack of motivationDisordersSymptomsClinical presentationDifferential diagnosisClinical managementDelusionsHallucinationsRisk factorsIncreased mortality
2023
Snoozing on Pot: Cannabis and Sleep
Skosnik P, Surti T. Snoozing on Pot: Cannabis and Sleep. 2023, 333-345. DOI: 10.1017/9781108943246.032.Peer-Reviewed Original ResearchConceptsMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsHealth teamsImpact of exposureCannabis dependenceAdverse effectsCannabisSynthetic cannabinoidsIllnessPsychosisCannabinoidsNew research findingsAssociationComplex associationNeurodevelopmentPutative modelSleepSchizophreniaRandomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvement
2022
Eulerian Phase-based Motion Magnification for High-Fidelity Vital Sign Estimation with Radar in Clinical Settings
Oshim F, Surti T, Goldfine C, Carreiro S, Ganesan D, Jayasuriya S, Rahman T. Eulerian Phase-based Motion Magnification for High-Fidelity Vital Sign Estimation with Radar in Clinical Settings. 2022, 00: 1-4. DOI: 10.1109/sensors52175.2022.9967051.Peer-Reviewed Original ResearchCitationsConceptsEulerian phaseFundamental frequency estimationMachine learning modelsFrequency estimationVital sign estimationMotion magnificationFilter outputSubtle motionsVital sign monitoringLearning modelHuman postureWavelength levelGabor filter outputsNoisy environmentsSign estimationDecomposition methodSmall objectsAccurate detectionMotionRadarMotion signalsEstimationGreater accuracyPhaseFFTIllness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.Peer-Reviewed Original ResearchCitationsConceptsIllness phasePotential critical windowsPhase-specific biomarkersDopaminergic abnormalitiesFunctional outcomeSpecialty careSymptom assessmentIllness stageChronic illnessClinical assessmentIllness trajectoryNeurophysiological biomarkersFunctional abnormalitiesClinical careEarly psychosisMemory dysfunctionPsychotic disordersTreatment targetsAllostatic adaptationIntervention windowClinical programsBrain developmentCritical windowDysfunctionIllness
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2018
168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal
Skosnik P, Cortes-Briones J, Creatura G, Morgan P, Ranganathan M, Deaso E, Surti T, D'Souza D. 168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal. Biological Psychiatry 2018, 83: s68. DOI: 10.1016/j.biopsych.2018.02.186.Peer-Reviewed Original Research
2015
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.
D'Souza D, Cortes-Briones J, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson R, Skosnik P. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2015, 1: 60-67. PMID: 29560896, DOI: 10.1016/j.bpsc.2015.09.008.Peer-Reviewed Original ResearchCitationsAltmetric
2001
Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking11PDB coordinates have been deposited with the RSCB with accession ID: 1F28.
Anderson A, O’Neil R, Surti T, Stroud R. Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking11PDB coordinates have been deposited with the RSCB with accession ID: 1F28. Cell Chemical Biology 2001, 8: 445-457. PMID: 11358692, DOI: 10.1016/s1074-5521(01)00023-0.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsStructure-based drug designProtein targetsDrug designFlexible residuesHigh-resolution crystal structuresProtein/ligand complexesNew conformationDrug leadsEnzyme conformational changeThymidylate synthaseCrystal structureStructure of enzymesPossible conformationsAccession IDConformational adaptationConformational changesLigand complexesExperimental kinetic dataDrug moleculesTarget siteResiduesActive siteAntifolate inhibitorsNovel ligandsKinetic data
1998
Structural models of the bovine papillomavirus E5 protein
Surti T, Klein O, Aschheim K, DiMaio D, Smith S. Structural models of the bovine papillomavirus E5 protein. Proteins Structure Function And Bioinformatics 1998, 33: 601-612. PMID: 9849943, DOI: 10.1002/(sici)1097-0134(19981201)33:4<601::aid-prot12>3.0.co;2-i.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBovine papillomavirus E5 proteinE5 dimerE5 proteinType II integral membrane proteinIntegral membrane proteinsPrevious mutagenesis studiesLigand-independent activationDisulfide-linked homodimerPDGF beta receptorMembrane proteinsTransmembrane orientationMutagenesis studiesMembrane bilayerCell transformationGenetic resultsProteinGln17Receptor moleculesMolecular scaffoldsComplex formationAsp33Computational searchDimerizationDimer structureDimers
Clinical Trials
Current Trials
M1 Schizophrenia PET Study
HIC ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsA longitudinal study of the effects of cannabis exposure on neuro-development in adolescents and young adults
HIC ID2000024543RoleSub InvestigatorPrimary Completion Date01/31/2021Recruiting ParticipantsGenderBothAge13 years - 25 yearsSleep Dependent Learning in Schizophrenia and Psychosis Risk Syndrome
HIC ID1201009524RolePrincipal InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18 years - 55 yearsTeen Brain and Behavior Study
HIC ID1111009332RoleSub InvestigatorPrimary Completion Date12/21/2022Recruiting ParticipantsGenderBothAge13 years - 17 years
Links & Media
News
- April 28, 2017Source: Schizophrenia Research
Yale study challenges 'self-medication' hypothesis of smoking, schizophrenia
- October 14, 2016
Fourteen Yale affiliates awarded NARSAD Young Investigator grants
- August 22, 2015Source: ECN
Dozen young Yale scientists honored for promising mental health research
- May 13, 2014
Godleski and telemental health team are honored by American College of Psychiatrists
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Lab Number
Office Fax Number